Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sipcam pacific australia pty. limited - soyal phospholipids; propionic acid - dispersible concentrate - soyal phospholipids ungrouped active 350.0 g/l; propionic acid acid-general active 350.0 g/l - surfactant - herbicide additive | activator | penetrant | post emergent herbicide | spreading adjuvant | surfactant | wetting agent - control of penetration | reduce alkaline hydrolysis | wetting agent (use as directed) | improve penetrating properties

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

macspred pty. ltd. - soyal phospholipids; propionic acid - dispersible concentrate - soyal phospholipids ungrouped active 350.0 g/l; propionic acid acid-general active 350.0 g/l - surfactant

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - soybean oil (unii: 241atl177a) (soybean oil - unii:241atl177a), medium-chain triglycerides (unii: c9h2l21v7u) (medium-chain triglycerides - unii:c9h2l21v7u), olive oil (unii: 6uyk2w1w1e) (olive oil - unii:6uyk2w1w1e), fish oil (unii: xgf7l72m0f) (fish oil - unii:xgf7l72m0f) - soybean oil 6 g in 100 ml - smoflipid is indicated in adult and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition (pn) when oral or enteral nutrition is not possible, insufficient, or contraindicated. use of smoflipid is contraindicated in patients with: - known hypersensitivity to fish, egg, soybean, peanut or any of the active or inactive ingredients in smoflipid [see warnings and precautions (5.3)] - severe disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglyceride >1,000 mg/dl) [see warnings and precautions (5.7)] risk summary administration of the recommended dose of smoflipid is not expected to cause major birth defects, miscarriage, or other adverse maternal or fetal outcomes. no animal reproduction studies have been conducted with smoflipid. there are risks to the fetus associated with severe malnutrition during pregnancy (see clinical considerations) . the estimated background risk of major birth defects and miscarriag

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - medium chain triglycerides, quantity: 60 g/l; fish oil - rich in omega-3 acids, quantity: 30 g/l; olive oil, quantity: 50 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: dl-alpha-tocopherol; water for injections; sodium hydroxide; egg lecithin; glycerol; sodium oleate - parenteral nutrition for adult patients when oral or enteral nutrition is impossible, insufficient or contraindicated.

United States - English - NLM (National Library of Medicine)

tmig, inc. - vitamin a (unii: 81g40h8b0t) (vitamin a - unii:81g40h8b0t), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), vitamin d (unii: 9vu1ki44gp) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol, d- (unii: n9pr3490h9) (.alpha.-tocopherol, d- - unii:n9pr3490h9), phytonadione (unii: a034se7857) (phytonadione - unii:a034se7857), thiamine (unii: x66nso3n35) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), niacinamide (unii: 25x51i8rd4) (ni - omega-3-acid ethyl esters capsules, usp are indicated as an adjunct to diet to reduce triglyceride (tg) levels in adult patients with severe (≥500 mg/dl) hypertriglyceridemia (htg). usage considerations : patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters capsules, usp and should continue this diet during treatment with omega-3-acid ethyl esters capsules, usp. laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters. every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consider

Malta - English - Medicines Authority

chiesi farmaceutici s.p.a via palermo 26/a, 43122 parma, italy - phospholipids - endotracheopulmonary instillation, suspension - phospholipids 80 mg/ml - other respiratory system products

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - vitamin a palmitate (unii: 1d1k0n0vvc) (vitamin a - unii:81g40h8b0t), ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc), .alpha.-tocopherol, dl- (unii: 7qwa1rio01) (.alpha.-tocopherol, dl- - unii:7qwa1rio01), phytonadione (unii: a034se7857) (phytonadione - unii:a034se7857) -

Singapore - English - HSA (Health Sciences Authority)

abbvie pte. ltd. - phospholipids - solution, sterile - 25 mg/ml - phospholipids 25 mg/ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

bharat parenterals limited - vitamin a, vitamin d3, alpha-tocopherol acetate, nicotinamide, thiamine (thiamine hydrochloride), pyridoxine (pyridoxine hydrochloride), riboflavin sodium phosphate, d-panthenol, vitamin b12, biotin, calcium glycerophosphate - solution for injection - 2000iu/ml+ 2000iu/ml+ 4mg/ml+ 100mg/ml+ 10mg/ml+ 5mg/ml+ 1mg/ml+ 1mg/ml+ 10mcg/ml+ 10mcg/ml+ 10mcg/ml

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dksh malaysia sdn. bhd. - phospholipids from soybeans -